Cargando…

Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders

Detalles Bibliográficos
Autores principales:	Westwell-Roper, Clara, Stewart, S. Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212432/ https://www.ncbi.nlm.nih.gov/pubmed/32425818 http://dx.doi.org/10.3389/fpsyt.2020.00264

Ejemplares similares

Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
por: Sethi, Rickinder, et al.
Publicado: (2019)

Prevalence of pediatric acute-onset neuropsychiatric syndrome (PANS) in children and adolescents with eating disorders
por: Aman, Marya, et al.
Publicado: (2022)

Biology of cyclooxygenase-2: An application in depression therapeutics
por: He, Ying, et al.
Publicado: (2022)

Commentary: Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
por: Zheng, Rui, et al.
Publicado: (2021)

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management
por: Rawat, Chitra, et al.
Publicado: (2019)

Challenges in the diagnosis and treatment of pediatric obsessive–compulsive disorder
por: Westwell-Roper, Clara, et al.
Publicado: (2019)

The Search for Cyclooxygenase-2 (COX-2) Inhibitors for the Treatment of Inflammation Disease: An in-silico Study
por: Ruslin, Ruslin, et al.
Publicado: (2022)

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
por: Smith, Francine G., et al.
Publicado: (2012)

Colorectal Carcinoma, Cyclooxygenases, and COX Inhibitors
por: Ganduri, Vinutna, et al.
Publicado: (2022)

Neurobiology of Behavior—Influences of Neuropsychiatric Disorders on Neurobiology and Behavior
por: Fakhoury, Marc, et al.
Publicado: (2023)

COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders
por: Müller, Norbert
Publicado: (2019)

Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
por: Harris, Randall E, et al.
Publicado: (2012)

Bioactivity of dihydropyrimidinone derivatives as inhibitors of cyclooxygenase-2 (COX-2): an in silico approach
por: Haq, Kautsar Ul, et al.
Publicado: (2023)

Integrated Neurobiology of Bipolar Disorder
por: Maletic, Vladimir, et al.
Publicado: (2014)

Expression of cyclooxygenase-2 (COX-2) in pituitary tumours
por: Sokołowski, Grzegorz, et al.
Publicado: (2012)

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
por: Harris, Randall E, et al.
Publicado: (2006)

Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
por: Ishiguro, Hiroki, et al.
Publicado: (2022)

Editorial: The Global Methamphetamine Problem: Approaches to Elucidate the Neurobiology, Epidemiology, and Therapeutic Effectiveness
por: Kohno, Milky, et al.
Publicado: (2020)

Editorial: The heterogeneity of neuropsychiatric disorders
por: Wu, Zhao-Min, et al.
Publicado: (2023)

Binding Energy Calculation of Patchouli Alcohol Isomer Cyclooxygenase Complexes Suggested as COX-1/COX-2 Selective Inhibitor
por: Raharjo, Sentot Joko, et al.
Publicado: (2014)

Editorial: Autism Spectrum Disorders: Developmental Trajectories, Neurobiological Basis, Treatment Update, Volume 2
por: Canitano, Roberto, et al.
Publicado: (2020)

Editorial: Neurobiological Underpinnings of Bipolar Disorder and Its Treatment
por: Singh, Balwinder, et al.
Publicado: (2021)

The neurobiology of functional neurological disorders characterised by impaired awareness
por: Milano, Beatrice Annunziata, et al.
Publicado: (2023)

Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View
por: Leung, Cheryl Cheuk-Yan, et al.
Publicado: (2019)

NMDA Receptor Activity in Neuropsychiatric Disorders
por: Lakhan, Shaheen E., et al.
Publicado: (2013)

Decreased food allergy-specific anxiety and increased general anxiety in parents of children with food allergies during the coronavirus disease 2019 pandemic
por: Westwell-Roper, Clara, et al.
Publicado: (2022)

Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
por: Harris, Randall E, et al.
Publicado: (2008)

COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease
por: Crofford, Leslie J
Publicado: (2003)

The Heterogeneity of Disruptive Behavior Disorders – Implications for Neurobiological Research and Treatment
por: Stadler, Christina, et al.
Publicado: (2010)

Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
por: Kakko, Johan, et al.
Publicado: (2019)

Editorial: Neurobiology, Clinical Course, and Therapeutic Approaches of Treatment-Resistant Schizophrenia: Toward an Integrated View
por: Iasevoli, Felice, et al.
Publicado: (2019)

Neurobiological Approach of Catatonia and Treatment Perspectives
por: Ellul, Pierre, et al.
Publicado: (2015)

Editorial: Neurobiological Perspectives in Behavioral Addiction
por: Choi, Jung-Seok, et al.
Publicado: (2019)

Neurobiological Determinants of Tobacco Smoking in Schizophrenia
por: Lucatch, Aliya M., et al.
Publicado: (2018)

Editorial: The neurobiology of suicide: the ‘suicidal brain'
por: Hocaoglu, Cicek
Publicado: (2023)

Editorial: Unravelling the role of CB2r in neuropsychiatric diseases
por: Onaivi, Emmanuel S.
Publicado: (2023)

New Challenges and Frontiers in the Research for Neuropsychiatric Disorders
por: Tropea, Daniela
Publicado: (2012)

Fragile X-Associated Neuropsychiatric Disorders (FXAND)
por: Hagerman, Randi J., et al.
Publicado: (2018)

Editorial: Glutamate-Related Biomarkers for Neuropsychiatric Disorders
por: Lin, Chieh-Hsin, et al.
Publicado: (2019)

Editorial: Temporal lobe dysfunction in neuropsychiatric disorder
por: Gao, Yujun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_guu0fe533q0h36gicsjr7h3i2i